To address the mechanisms underpinning the translational and clinical performance of EFIRM, we directly compared EFIRM with ddPCR on a cohort of NSCLC patients for the two front-line sensitizing EGFR mutations in biofluids (plasma and saliva). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.